Cordyceps Sunshine Biotech Holdings (RAJAF) Total Current Liabilities (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $5.2 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 4.12% year-over-year to $5.2 million; the TTM figure through Dec 2025 stood at $5.2 million (up 4.12% YoY), while the FY2025 annual figure was $5.2 million, up 4.12% from the prior year.
• Total Current Liabilities was $5.2 million for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $5.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.2 million in Q4 2025 to a low of $1.5 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $3.3 million across 5 years, with a median of $2.9 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities declined 13.71% in 2022, then jumped 68.12% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $2.9 million in 2021, then slipped by 13.71% to $2.5 million in 2022, then increased by 17.65% to $3.0 million in 2023, then surged by 68.12% to $5.0 million in 2024, then climbed by 4.12% to $5.2 million in 2025.
• The last three Total Current Liabilities figures came in at $5.2 million (Q4 2025), $5.0 million (Q4 2024), and $3.0 million (Q4 2023), per Business Quant data.